All funding news

Biotech funding news

20 recent Biotech rounds across our tracked sources.

纽
🇨🇳

纽邦生物

Nutritional Supplements

纽邦生物 supplies dietary supplement raw materials to 600+ brands across China.

$28MSeries C+
Investor undisclosed
A $28M Series C+ for a supplement ingredient supplier signals China's nutraceutical market is consolidating around reliable, scaled manufacturers—this isn't about innovation hype, it's about supply chain defensibility. If you're building in adjacent health categories (functional foods, beauty-from-within, etc.), this shows there's real capital for B2B players who can lock in 600+ brand relationships and handle regulatory complexity. The round size suggests they're likely investing in vertical integration or geographic expansion rather than R&D, which means the moat is operational, not scientific.
D
🇨🇳Drug FarmDrug Discovery

Drug Farm accelerates pharmaceutical development through advanced drug discovery platforms for global biotech and pharma companies.

$55MSeries D
Investor undisclosed
A $55M Series D for a Chinese drug discovery platform signals that computational biotech is maturing past hype—this isn't seed-stage AI-for-drugs anymore, it's capital flowing to companies with actual pharma customer traction. If you're building B2B tools for regulated industries (biotech, medtech, materials), this validates that enterprises will pay for platforms that compress timelines, even if adoption cycles are long.
A
Allotera TherapeuticsTherapeutics

Allotera Therapeutics develops allogeneic cell therapies for treating serious diseases.

$35M
Investor undisclosed
A $35M Series A for allogeneic cell therapy signals that off-the-shelf cell manufacturing is finally hitting the risk/reward sweet spot for investors—manufacturing scale and immune tolerance are becoming solvable, not theoretical. At this stage and size, Allotera is likely burning cash on GMP manufacturing, clinical trial setup, and IP moats around their allogeneic platform. If you're building in adjacent biotech (gene therapy, regenerative medicine, or even synthetic biology), watch whether they can actually solve the cost-per-dose problem that's killed previous allogeneic plays—that's the real gate.
德
🇨🇳

德睿智药

Pharmaceutical

德睿智药 develops AI-designed weight loss pharmaceuticals with Phase 3 clinical candidates.

$52MSeries B
Investor undisclosed
A $52M Series B for an AI-designed weight loss drug hitting Phase 3 signals China's biotech is moving past me-too generics into genuine drug discovery—and that obesity pharma is hot enough to fund even in a crowded space. If you're building biotech tooling or clinical-stage anything, watch whether Chinese VCs start demanding AI-designed candidates as table stakes; this round suggests they might.
B
🇨🇳BrainCoBrain-Computer Interface

BrainCo develops brain-computer interface technology that decodes neural signals for medical and commercial applications.

$2.8BPre-IPO
Investor undisclosed
A $2.8B pre-IPO round for a Chinese BCI company signals that neural decoding has moved from research curiosity to capital-scale commercialization—likely driven by regulatory clarity in China and real clinical/consumer traction. At this stage and size, they're probably scaling manufacturing, building out clinical evidence for specific indications (motor control, communication), and preparing for public markets. If you're in adjacent neurotech, assistive devices, or even consumer health hardware, watch their go-to-market playbook closely—this validates that the regulatory and reimbursement path exists, even if it's China-first.
B
Beeline MedicinesDrug Discovery

Beeline Medicines uses AI to discover and develop novel drugs faster and more efficiently than traditional methods.

$126.3MSeries A Extension
Investor undisclosed
A $126M Series A extension signals that AI drug discovery has moved past the hype phase—investors are now betting on execution and clinical validation, not just the promise of faster screening. Beeline likely uses this to push candidates through preclinical/early clinical stages and prove the AI model actually reduces time-to-IND. If you're building in adjacent biotech infrastructure (lab automation, data platforms, regulatory tech), this validates that deep-pocketed founders will pay for tools that compress the discovery bottleneck.
华
🇨🇳

华源智因

AI Drug Discovery

华源智因 uses AI to model human cells and predict drug efficacy for pharmaceutical development.

UndisclosedSeed
Investor undisclosed
Biobot Surgical logo
🇸🇬Biobot SurgicalMedical Robotics

Biobot Surgical builds robotic-assisted platforms for precise prostate biopsies and ablations using MRI-ultrasound fusion guidance.

$15.6MSeries B
C
ClavystBio
Z
A $15.6M Series B for a precision robotics play in urology signals that MRI-guided interventions are moving from research into reimbursable procedures—this is about de-risking the clinical pathway, not just building cooler hardware. If you're in adjacent image-guided surgery spaces (cardiac, orthopedic), watch whether Biobot's fusion approach becomes a standard-of-care requirement that forces your own roadmap.
O
Oblenio BioBiotech

Oblenio Bio develops novel therapeutics for metabolic and inflammatory diseases using proprietary biology platforms.

$62MSeries B
Investor undisclosed
A $62M Series B for a metabolic/inflammatory biotech signals investors are still backing platform plays in this space, but the bar is clearly higher—they need differentiated biology, not just another GLP-1 me-too. If you're building in adjacent areas (diagnostics, digital health for metabolic disease, or supply chain for biotech), this validates that the category has real capital velocity, but you'll need a defensible angle to compete for that same investor attention.
R
🇺🇰RQ BioBiotech

RQ Bio develops cell therapy manufacturing technology for biotech and pharma companies.

$108.6MSeries A
Investor undisclosed
A $108M Series A for manufacturing tech (not the therapy itself) signals that cell therapy scaling has moved from R&D bottleneck to commercialization bottleneck—investors are betting the hard part now is making it at volume, not inventing it. If you're building biotech infrastructure, this validates that the market will pay for solutions that compress manufacturing timelines and costs, not just efficacy gains.
Ollin Biosciences logo
Ollin BiosciencesBiotech

Ollin Biosciences develops cell therapy manufacturing platforms to scale production of regenerative medicines.

$330MSeries B
Investor undisclosed
A $330M Series B for cell therapy manufacturing signals that the bottleneck has shifted from drug discovery to production—investors are betting the clinical wins are real enough that scale is now the constraint. At this stage and size, Ollin is likely building out GMP facilities and automation to hit cost/throughput targets that make these therapies economically viable. If you're in adjacent biotech infrastructure (diagnostics, logistics, quality control), this validates that there's serious capital flowing to solve the "how do we make this at scale" problem, not just the "does it work" problem.
M
Memento MedicinesDrug Development

Memento Medicines develops novel therapeutics for neurodegenerative diseases using proprietary drug discovery platforms.

$93MSeries A
Investor undisclosed
A $93M Series A for early-stage neuro therapeutics signals serious institutional conviction in platform-based drug discovery—this isn't a single-asset bet. If you're building in adjacent biotech (diagnostics, patient data, manufacturing), this validates that deep-tech biotech rounds are still getting funded at scale despite macro headwinds, which means your Series A bar is probably higher but the capital exists if your unit economics are defensible.
Kardigan logo
🇺🇸KardiganCardiology

Kardigan develops cardiovascular therapeutics to treat heart disease.

$400MIPO
Investor undisclosed
A $400M cardiology IPO in mid-2026 signals that late-stage biotech can still access public markets if they have clinical validation—but the bar is high and the window is narrow. If you're building in adjacent therapeutic areas (metabolic disease, pulmonary hypertension), this shows investors will fund the path to Phase 3 data, but you'll need to prove efficacy before the IPO window closes.
Cellares logo
CellaresCell & Gene Therapy Manufacturing

Cellares automates cell and gene therapy manufacturing to reduce production costs and timelines for developers.

$50MSeries D
Investor undisclosed
A $50M Series D for manufacturing automation in cell/gene therapy signals investors still believe the unit economics problem is solvable—not that the therapy pipeline itself is heating up. Cellares is likely burning this on scaling their platform hardware and hiring ops/engineering to land their first 5-10 anchor customers at scale. If you're building anything in biotech infrastructure (lab automation, supply chain, QA software), this validates that VCs will fund the unsexy-but-critical layer if you can prove you actually reduce COGS or time-to-clinic by a meaningful percentage.
Zumutor Biologics logo
🇺🇸Zumutor BiologicsImmunotherapy

Zumutor develops NK cell checkpoint immunotherapies to enhance natural killer cell activity against tumors.

$7.3MSeries B
Investor undisclosed
A $7.3M Series B for NK cell immunotherapy signals that checkpoint modulation (beyond the saturated PD-1/PD-L1 space) is attracting serious capital—especially with Accel backing, which rarely touches biotech unless the science is differentiated. They're likely funding IND-enabling studies and early clinical work, which means the NK cell thesis has moved past pure R&D into validation. If you're building in adjacent cell therapy or checkpoint biology, this validates that investors are willing to fund the harder immunology problems when the mechanism is genuinely novel.
Kardigan logo
🇺🇸KardiganCardiology

Kardigan develops cardiovascular therapeutics to treat heart disease.

UndisclosedIPO
Investor undisclosed
B
🇨🇳BoruikangBrain-Computer Interface

Chinese BCI company developing non-invasive and invasive brain-computer interface medical devices, including EEG acquisition systems, transcranial electrical stimulation devices, and the NEO-ONE SCI invasive BCI.

$350MIPO
Investor undisclosed
A $350M IPO for a Chinese BCI company signals that invasive neural interfaces are moving from research curiosity to regulated medical product—the bar for going public on hardware this complex is high. If you're building in neurotech, adjacent biodevices, or clinical software, watch how Boruikang navigates FDA/CE approval timelines and reimbursement; Chinese regulatory wins often preview what Western markets will accept 18-24 months later.
Fesarius Therapeutics logo
Fesarius TherapeuticsTherapeutics

Fesarius Therapeutics develops novel therapeutic treatments targeting unmet medical needs in disease areas.

$20MSeries A
Investor undisclosed
A $20M Series A for an early-stage biotech with vague positioning and undisclosed backers is a yellow flag—either the company is genuinely early-stage (pre-clinical or single-target) or the round details are being kept quiet for IP reasons. If you're building in adjacent biotech spaces, watch whether Fesarius publishes data in the next 12-18 months; silent fundraising often means either a pivot or a long runway before proof-of-concept, which affects how you think about your own validation timeline.
B
🇨🇳Batai MedicalBiotech

Batai Medical develops biotech solutions for the Chinese healthcare market.

$280KSeries D
Investor undisclosed
A $300K Series D in 2026 is a red flag—either this is a down round or the company is in serious trouble. If Batai is still fundraising at this stage with this amount, it suggests the China biotech market is either consolidating hard or this company lost momentum with earlier backers. If you're building biotech in Asia, watch whether Chinese VCs are rotating away from early-stage biotech entirely.
巴
🇨🇳

巴泰医疗

Medical Devices

Batai Medical develops innovative medical devices for clinical diagnostics and patient monitoring in China.

$28MSeries D
Investor undisclosed
A $28M Series D for a Chinese diagnostic device company signals that domestic medtech is moving past import-substitution into actual innovation—investors are still backing hardware plays in China despite global skepticism. At this stage, the capital likely funds manufacturing scale-up and clinical validation for regulatory approval, not R&D. If you're building in adjacent diagnostics or monitoring, watch whether Batai pursues direct-to-hospital sales or DTC channels; that playbook will tell you how much pricing power Chinese medtech actually has versus Western incumbents.